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Abstract: Basal cell carcinoma (BCC) is the most common human malignancy. Recent
advances in our understanding of the critical biologic pathways implicated in the development
and progression of BCC have led to the development of the first molecular targeted therapy for
this disease. The hedgehog pathway is mutated in virtually all patients with BCC and recent trials
with vismodegib, an inhibitor of this pathway, have shown significant responses. This review
will discuss the importance of the hedgehog pathway in the pathogenesis of BCC and describe
in detail the pharmacology of vismodegib in relation to its activity in advanced BCC.
Keywords: basal cell carcinoma, vismodegib, hedgehog pathway

Introduction
Basal cell carcinoma (BCC) is the most common human malignancy. Since it is not always
included in cancer registries, the true incidence is unknown. It is estimated that approximately 3.5 million nonmelanoma skin cancers in 2.2 million patients are treated annually
in the United States, the majority of which are BCC (American Cancer Society, Facts
and Figures 2013). The American Academy of Dermatology estimates that approximately
2 million BCC are treated every year (http://www.aad.org/dermatology-a-to-z/diseasesand-treatments/a---d/basal-cell-carcinoma). Fortunately, these tumors are usually amenable
to local therapy and only 1%–5.3% of lesions recur after initial resection.1
Interestingly, even locally aggressive tumors seldom metastasize and metastatic
BCC is quite rare. Since accurate incidence records of this disease are not available,
the burden of metastatic disease is difficult to ascertain. Rates ranging from 0.0028% to
0.55% of patients with BCC developing metastases have been reported,2–7 but even
these have been questioned.8 The median age of patients with metastatic BCC at the
time of diagnosis of the primary lesion is about 45–56 years, and metastases appear at
a median of about 9 years later.9–11 Factors that may predispose to the development of
metastatic BCC include male gender,9 primary lesion in the ear region9,11,12 and face,11
large11 and locally invasive13 primary tumors, recurrence following initial treatment,11
and impairment of cell mediated immunity (eg, acquired immunodeficiency syndrome,
therapeutic immunosuppression).14,15
Recent advances in our understanding of the biologic pathways that appear to be
important in the development and progression of BCC have led to the development of
the first molecular targeted therapy for this disease, vismodegib. The hedgehog (Hh)
pathway is mutated in virtually all patients with BCC and inhibition of this pathway
with vismodegib appears to result in significant clinical responses. The following
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sections will discuss the importance of the Hh pathway in the
pathogenesis of BCC and describe in detail the pharmacology
of vismodegib in relation to advanced BCC.

Hh pathway and its role in BCC
The Hh pathway is one of the most common signal
transduction pathways used by mammalian cells16 for normal
embryonic development of the neural tube, axial skeleton,
skin, and hair,17 and for wound healing during postnatal life.18
While this pathway appears to be silenced in most adult
tissues,19 it has been shown to promote the proliferation of
stem cells from various tissues in the adult. These include
hematopoietic cells,20 mammary,21 mesenchymal,22 and
neural23 stem cells. This pathway also appears to play a
role in the transition of hair follicles from the resting to the
growth phase.24 This could explain the alopecia noted in
patients treated with the Hh pathway inhibitor, vismodegib.
In addition, this pathway seems to be involved in the repair
of various organs in the adult following injury.25–27

Recent studies have shown that aberrant Hh signaling
pathway is involved in the pathogenesis, self-renewal of stem
cells, and chemotherapeutic resistance of BCC.28,29 Besides
BCC, Hh signaling is also activated in other malignancies
such as medulloblastoma,30,31 colon,32 prostate,33,34 breast,35
lung,36 and various hematologic malignancies.37–40 The Hh
pathway dependent gene upregulation leads to increased
cell proliferation and cell survival, and promotes bone
metastases.41 This pathway has been shown to regulate the
epithelial–mesenchymal transition and dissemination of
cancer stem cells in solid tumors,42,43 and enhance metastatic
disease progression.44 These observations suggest that
targeted inhibition of Hh signaling may be an effective
treatment strategy for several human cancers.
The signaling cascade of the Hh pathway in mammalian
cells is initiated by binding of one of three Hh ligands (sonic,
Indian, or desert Hh) to the 12 pass transmembrane receptor
patched 1 (Ptch1) (Figure 1). This causes internalization and
degradation of Ptch1, thereby releasing smoothened (SMO),
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SHh

SHh

SHh
SMO

SMO

SMO

Ptch1

Inactive SMO

Inhibited SMO

Ptch1
Active SMO

SUFU

SUFU
Activation and
nuclear translocation

Proteosomal
degredation
Gli3

Gli2

No Gli activation

Gli3

Gli1

Gli2

Gli1
No nuclear translocation

Gli1

Gli2

Nucleus

Gli1
Ptch1
Ptch2
Bcl2
Cyclin D1
c-Myc
VEGF

Figure 1 A schematic diagram showing inhibition of Hedgehog (Hh) signaling by vismodegib.
Notes: The extracellular Hh ligands (Sonic, Indian, or Desert Hh) bind to Patched 1 (Ptch1), relieving the inhibition of Smoothened (SMO) by Ptch1. SMO disrupts the
cytoplasmic complex containing the Suppressor of Fused (SUFU)-glioma-associated oncogene homologue (Gli) complex resulting in degradation of Gli3 and translocation of
Gli1 and Gli2 to the nucleus to upregulate target genes like Ptch1, Gli1, c-Myc, Bcl2, vascular endothelial growth factor, and cyclin D1. Vismodegib binds to the extracellular
domain of SMO, markedly inhibiting the release and translocation of Gli1 and Gli2 to the nucleus.
Abbreviations: Gli, glioma-associated oncogene homologue; Ptch1, patched 1; SHh, sonic hedgehog; SMO, smoothened; SUFU, Suppressor of Fused; VEGF, vascular
endothelial growth factor.
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a 7 pass transmembrane G protein coupled receptor
like protein. This protein then enters the primary
cilia and disrupts the cytoplasmic complex containing
Suppressor of Fused (SUFU)-glioma-associated oncogene
homologue (Gli). The SUFU regulates transcriptional
factors (Glis) through posttranslational modifications like
phosphorylation, sumoylation, and selective proteolysis.45
Release of Gli transcription factors (Gli 1–3) from SUFU
inhibition results in nuclear translocation and upregulation
of Gli1 associated target genes that include Gli1, Ptch1,
cyclin D1, c-Myc, vascular endothelial growth factor, Bcl2, and snail, depending upon cell type46 and degradation of
the repressor transcription factor Gli3. Depending on the
Gli2 posttranscriptional and posttranslational processing
events, Gli2 has been shown to act as either a positive or
negative regulator of Hh pathway signaling.47 Deregulated
Hh signaling has been associated with either mutations in
pathway genes or overexpression of signaling molecules
in either tumor cells themselves or in cells within the
supportive tumor microenvironment.46,48–51
The first link between the Hh pathway and BCC came
from the discovery of loss-of-function mutations of
Ptch1 gene in Gorlin syndrome.29,52 Patients with Gorlin
syndrome are strongly predisposed to the development of
BCC at an early age. Recent molecular and genetic studies
have shown that almost all BCC tumors contain genetic
alterations in components of the Hh signaling pathway
and these tumors have elevated Ptch and Gli1 messenger
(m)RNA levels.53,54 This ligand-independent mechanism
of Hh activation, driven by specific Hh gene mutations
within the tumor cells, is termed Type I Hh signaling.46 It
has been estimated that almost 90% of sporadic BCCs have
loss-of-function mutation in at least one allele of Ptch1
and in addition, around 10% have activating mutations in
the SMO, rendering it resistant to Ptch1 inhibition.28,55–57
In contrast, mutations in other downstream molecules
of the Hh pathway appear to be rare in BCC. In a study
of 42 patients with sporadic BCC, only two patients had
mutations in SUFU, one of which was a missense mutation
and the other a silent mutation.58 No mutation was seen
in Gli1.

Pharmacology of vismodegib
Structure
Vismodegib is an orally active SMO inhibitor (2-chloroN-[4-chloro-3-pyridin-2-yl-phenyl]-4-methanesulfonyl
benzamide) with a molecular weight 421.30 g/mol
(Figure 2).
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Figure 2 Chemical structure of vismodegib.
Note: Structure of vismodegib is courtesy of Genentech.

Preclinical evidence
Vismodegib was shown to be effective in suppressing Gli in
the Hh responsive tumor cell line CALU-6 when implanted
in nude mice.59 It was also effective in producing complete
regression of the Hh pathway dependent medulloblastoma
allograft model generated from Ptch / mice.59

Pharmacokinetics
Vismodegib has an unusual pharmacokinetic profile. It
demonstrates saturable absorption with a dose dependent
increase in absorption until a dose of 540 mg, beyond which
the degree of absorption does not appear to increase.60 This
could explain the plateau of the rise in concentration of the
drug within the first 14 days. The drug reaches its steady
state concentration in the plasma in about 7–14 days after
initiation of therapy. Vismodegib is highly protein bound to
albumin and A1-acid glycoprotein. Plasma concentrations
of total vismodegib appear to be strongly correlated with
A1-acid glycoprotein levels.60,61 Food does not seem to affect
the degree of absorption of vismodegib.
Vismodegib undergoes oxidation mediated by
the cytochrome P450 (CYP) enzymes CYP2C9,
CYP3A4, and CYP3A5, and the oxidative metabolites
are excreted in the feces. 62,63 In addition, vismodegib
undergoes glucuronidation and pyridine ring cleavage
to a smaller extent.62 A study in dogs and rats found that
a small proportion of the drug was metabolized by an
uncommon pyridine ring opening.64 These metabolites
were excreted in the feces as well. In pharmacokinetic
studies, vismodegib had an elimination half-life of
approximately 12 days after a single dose. However this
duration decreased to 4 days after repeated, once-daily
administration, suggesting an increased clearance with
repeated administration.65
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Although it has not been specifically studied, based on the
pharmacokinetic profile, it is unlikely that renal dysfunction
affects the safety profile of vismodegib significantly. Hence,
patients with renal dysfunction are not likely to need a
modification of their dose. The need for dose modification in
patients with hepatic dysfunction is currently unknown.

Pharmacodynamics
Vismodegib binds to, and inactivates, SMO. This prevents
its translocation when Ptch1 is stimulated by Hh ligands and
leads to the inhibition of the downstream signaling pathways
and a decrease in the production of downstream proliferation
factors (Figure 1).66
Exposure to vismodegib leads to the downregulation
of Gli1. In a Phase I trial of vismodegib in patients
with locally advanced or metastatic solid tumors there
was 2 fold downmodulation of Gli1 expression in
skin biopsies from almost 75% patients, compared with
pretreatment specimens.66 In the same study, a similar
proportion of patients with BCC showed 2 fold downmodulation of Gli1 expression. However, the downmodulation of Gli1 expression was not associated with
plasma concentrations of the drug.

Adverse effects
Vismodegib is relatively well tolerated. The most common
adverse reactions seen in clinical trials have been muscle
spasms (70%), alopecia (60%), dysgeusia (55%), weight
loss (45%), fatigue (40%), nausea (30%), diarrhea (30%),
decreased appetite (25%), constipation (20%), arthralgias (15%),
vomiting (12%), and ageusia (10%).67 Approximately 30%
of premenopausal women developed amenorrhea while on
vismodegib. Other laboratory abnormalities noted by patients
on clinical trials included hyponatremia (4%), hypokalemia
(1%), and azotemia (2%). A recent report described the
development of keratoacanthomas in two patients, who did
not have a history of previous squamous cell carcinomas,
while being treated with vismodegib.68 While the authors were
not able to establish a causal relationship with vismodegib,
clinicians need to be alert to these findings.
The vismodegib package insert contains a black box warning
regarding the risk of severe birth defects and embryonic fetal
death. This is based on rat studies, which demonstrated that
vismodegib administered at a dose of 10 mg/kg/day showed
teratogenic effects.69 This dose corresponds to an exposure of
approximately 20% of the human exposure at the recommended
dose of 150 mg daily. Similarly, there is a potential risk of
exposure to the drug through semen. Hence, sexually active
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individuals receiving vismodegib should be advised of the need
for contraception (Source: Erivedge™ package insert. http://
www.gene.com/download/pdf/erivedge_prescribing.pdf).

Drug resistance
Resistance mechanisms to vismodegib have not been
extensively studied, which is understandable given the
relatively short clinical experience with this drug. However,
anecdotal reports of acquired resistance to vismodegib are
beginning to emerge. In the only case reported thus far,
a 26 year old man with treatment refractory metastatic
medulloblastoma who was treated with vismodegib responded
initially, but developed progressive disease after 3 months,
suggesting the development of resistance. A molecular
analysis of the biopsy specimen obtained at disease
progression showed a heterozygous G to C missense mutation
at position 1697, which is responsible for a change in codon
473 from aspartic acid to histidine (D473H).70 This mutation
prevents the binding of vismodegib to SMO, thereby leading
to resistance.
This was further studied in vitro by Dijkgraaf et al who
replaced the aspartic acid at position 473 of the SMO gene
with every other amino acid and found that vismodegib
did not bind to SMO in any of the mutant variations,
thereby suggesting that D473 is critical for SMO binding
by vismodegib.71 It is unclear, however, if D473 is directly
involved in the binding of vismodegib or if its main role is to
maintain the necessary SMO conformation for binding.
Other potential resistance mechanisms identified in vitro
include mutations at E518.71 Substitution of glutamic acid
at this site conferred complete resistance to vismodegib.
Other possible mechanisms of resistance include focal
amplifications of the transcription factor Gli2 and the target
gene Ccnd1, which exert their actions downstream of SMO.71
There are initial data on resistance to vismodegib in BCC,
which are described below.
Mechanisms to overcome this resistance are currently
being studied. Dijkgraaf et al71 screened multiple chemically
diverse Hh pathway inhibitors and were able to identify
several compounds that were active against the two known
SMO resistance mutations, SMO-D473H and SMO-E518K.
Available data also suggest that Hh pathway resistant
medulloblastoma allografts may respond to inhibition of
phosphoinositide-3-kinase.71

Clinical data on vismodegib
The Phase I trial of vismodegib included 68 patients with
different malignancies, of which 33 had advanced BCC.66
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Vismodegib was well tolerated with only six patients
(8.8%) developing grade 4 adverse events (hyponatremia,
fatigue, pyelonephritis, presyncope, resectable pancreatic
adenocarcinoma, and paranoia with hyperglycemia).
A maximum tolerated dose was not reached and based on
achievement of maximal plasma concentration and response,
the recommended Phase II dose was 150 mg daily. Interestingly,
20 patients (19 with BCC and one with medulloblastoma) had
a response based on Response Evaluation Criteria in Solid
Tumors (RECIST) criteria.72 At the time of publication, the
median duration of response in patients with advanced BCC
was 12.8 months (range 3.7–26.4 months). This led to further
investigation of vismodegib in BCC.
A multicenter, international, two cohort, nonrandomized
Phase II study, administered 150 mg of oral vismodegib daily
to patients with either metastatic or locally advanced BCC
(inoperable disease or for whom surgery was inappropriate,
ie, multiple recurrences and a low likelihood of cure, or
substantial anticipated disfigurement).73 The response
rate was 30% for patients with metastatic BCC and 43%
(21% complete response) in patients with locally advanced
BCC. The median duration of response was 7.6 months in
both cohorts. The most common adverse events were muscle
spasms, alopecia, dysgeusia, weight loss, and fatigue. Serious
adverse events were reported in 25% of patients. Seven deaths
were reported, although their relationship to the study drug
was unclear. The results of these studies led to the approval of
vismodegib for the treatment of metastatic BCC and locally
advanced BCC in patients who are not candidates for surgery
or radiation based on the location or size of the lesion.
More recently, vismodegib has been studied for its
potential to prevent the development of BCC in patients
with basal cell nevus syndrome. In a randomized placebo
controlled trial, 42 patients with the basal cell nevus
syndrome were randomly assigned to either vismodegib
(150 mg daily) or placebo for 18 months.74 The primary
end point of this study was the rate of development of new
BCC that were eligible for surgical resection. Vismodegib
significantly reduced the rate of new surgically eligible basal
cell carcinomas when compared to placebo (2 versus 29 new
surgically eligible BCC per group annually; P
0.001).
Vismodegib also reduced the size of existing BCC (median
decrease 71%) when compared to placebo (median decrease
21%; P  0.003). Patients receiving vismodegib had fewer
surgeries for BCC (mean of 0.31), compared with those
receiving placebo (mean 4.4; P 0.001). Palmar and plantar
pits, pathognomonic signs of the basal cell nevus syndrome,
also disappeared with vismodegib. However, almost half of
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the patients had to discontinue treatment due to drug related
adverse events.
Recently, an interesting phenomenon of tumor regrowth
was reported in patients treated with vismodegib. 75 In
a retrospective analysis of 28 patients on vismodegib,
Chang et al noted tumor regrowth within or adjacent
to (1 cm) the prior tumor bed in 6 (21%) patients.75
Surprisingly, none of the eight patients with metastatic
BCC in their analysis demonstrated regrowth after initial
shrinkage. Hence, close clinical examination of patients,
even examination of those who have a response to therapy, is
warranted to detect the development of secondary resistance
to vismodegib. These findings would also suggest that
vismodegib and other agents targeting the Hh pathway are
unlikely to cure BCC, and surgery still would be considered
the best curative option for patients who can undergo the
procedure without major cosmetic deformity.

Conclusion
The Hh pathway is critical to the development of BCC.
Mutations in this pathway are seen in virtually all patients
with BCC. Inhibition of this pathway with the SMO inhibitor,
vismodegib, leads to significant responses in patients with
metastatic and locally advanced BCC. While vismodegib can
delay the development of BCC in patients with the basal cell
nevus syndrome, its adverse effect profile tempers its use in this
setting. Finally, there are reports of resistance to vismodegib
and those mechanisms are currently being studied.

Acknowledgments
The authors on this manuscript, in part, were supported by
the VA Career Development Award (AKG) and NIH grants
(UO1 EDRN CA 111294, P50 SPORE CA127297, and U54
TMEN CA160163) (SKB).

Disclosure
The authors report no conflicts of interest in this work.

References
1. Thissen MR, Neumann MH, Schouten LJ. A systematic review of
treatment modalities for primary basal cell carcinomas. Arch Dermatol.
1999;135:1177–1183.
2. Paver K, Poyzer K, Burry N, Deakin M. Letter: The incidence of basal
cell carcinoma and their metastases in Australia and New Zealand.
Australas J Dermatol. 1973;14:53.
3. Cade S. Malignant Disease and its Treatment by Radium. Baltimore:
Williams and Wilkins Company; 1940.
4. Cotran RS. Metastasizing basal cell carcinomas. Cancer. 1961;14:
1036–1040.
5. Lakshmipathi T, Hunt KM. Metastasizing basal-cell carcinoma. Br J
Dermatol. 1967;79:267–270.

submit your manuscript | www.dovepress.com

Dovepress

201

Macha et al
6. Scanlon EF, Volkmer DD, Oviedo MA, Khanedar JD, Victor TA.
Metastatic basal cell carcinoma. J Surg Oncol. 1980;15:171–180.
7. Wronkowski Z. Przerzuty raka podstawnokomorkowego skory [Metastases in dermal basal cell carcinoma.] Nowotwory. 1968;18:51–55.
Polish.
8. Wadhera A, Fazio M, Bricca G, Stanton O. Metastatic basal cell
carcinoma: a case report and literature review. How accurate is our
incidence data? Dermatol Online J. 2006;12:7.
9. von Domarus H, Stevens PJ. Metastatic basal cell carcinoma. Report of
five cases and review of 170 cases in the literature. J Am Acad Dermatol.
1984;10:1043–1060.
10. Weiss GJ, Korn RL. Metastatic basal cell carcinoma in the era of hedgehog signaling pathway inhibitors. Cancer. 2012;118:5310–5319.
11. Snow SN, Sahl W, Lo JS, et al. Metastatic basal cell carcinoma. Report
of five cases. Cancer. 1994;73:328–335.
12. Lo JS, Snow SN, Reizner GT, Mohs FE, Larson PO, Hruza GJ.
Metastatic basal cell carcinoma: report of twelve cases with a review
of the literature. J Am Acad Dermatol. 1991;24:715–719.
13. Berlin JM, Warner MR, Bailin PL. Metastatic basal cell carcinoma
presenting as unilateral axillary lymphadenopathy: report of a case and
review of the literature. Dermatol Surg. 2002;28:1082–1084.
14. Sitz KV, Keppen M, Johnson DF. Metastatic basal cell carcinoma
in acquired immunodeficiency syndrome-related complex. JAMA.
1987;257:340–343.
15. Walling HW, Fosko SW, Geraminejad PA, Whitaker DC, Arpey CJ.
Aggressive basal cell carcinoma: presentation, pathogenesis, and
management. Cancer Metastasis Rev. 2004;23:389–402.
16. Merchant JL. Hedgehog signalling in gut development, physiology and
cancer. J Physiol. 2012;590:421–432.
17. Tang JY, So PL, Epstein EH Jr. Novel Hedgehog pathway targets against
basal cell carcinoma. Toxicol Appl Pharmacol. 2007;224:257–264.
18. Barakat MT, Humke EW, Scott MP. Learning from Jekyll to control
Hyde: Hedgehog signaling in development and cancer. Trends Mol
Med. 2010;16:337–348.
19. Ingham PW, McMahon AP. Hedgehog signaling in animal development:
paradigms and principles. Genes Dev. 2001;15: 3059–3087.
20. Bhardwaj G, Murdoch B, Wu D, et al. Sonic hedgehog induces
the proliferation of primitive human hematopoietic cells via BMP
regulation. Nat Immunol. 2001;2:172–180.
21. Liu S, Dontu G, Mantle ID, et al. Hedgehog signaling and Bmi-1
regulate self-renewal of normal and malignant human mammary stem
cells. Cancer Res. 2006;66:6063–6071.
22. James AW, Pang S, Askarinam A, et al. Additive effects of sonic
hedgehog and Nell-1 signaling in osteogenic versus adipogenic
differentiation of human adipose-derived stromal cells. Stem Cells Dev.
2012;21:2170–2178.
23. Ahn S, Joyner AL. In vivo analysis of quiescent adult neural stem cells
responding to Sonic hedgehog. Nature. 2005;437:894–897.
24. Paladini RD, Saleh J, Qian C, Xu GX, Rubin LL. Modulation of hair
growth with small molecule agonists of the hedgehog signaling pathway.
J Invest Dermatol. 2005;125:638–646.
25. Michelotti GA, Xie G, Swiderska M, et al. Smoothened is a master
regulator of adult liver repair. J Clin Invest. Epub April 8, 2013.
26. Zarogoulidis P, Zarampouka K, Huang H, et al. Hedgehog signaling
pathway: the must, the maybe and the unknown. J Thorac Dis. 2013;5:
195–197.
27. Wang S, Hyun J, Youn B, Jung Y. Hedgehog signaling regulates the
repair response in mouse liver damaged by irradiation. Radiat Res.
2013;179:69–75.
28. Gailani MR, Stahle-Backdahl M, Leffell DJ, et al. The role of the human
homologue of Drosophila patched in sporadic basal cell carcinomas.
Nat Genet. 1996;14:78–81.
29. Hahn H, Christiansen J, Wicking C, et al. A mammalian patched
homolog is expressed in target tissues of sonic hedgehog and maps to
a region associated with developmental abnormalities. J Biol Chem.
1996;271:12125–12128.

202

submit your manuscript | www.dovepress.com

Dovepress

Dovepress
30. Zurawel RH, Allen C, Chiappa S, et al. Analysis of Ptch/SMO/SHH
pathway genes in medulloblastoma. Genes Chromosomes Cancer.
2000;27:44–51.
31. Bar EE, Chaudhry A, Farah MH, Eberhart CG. Hedgehog signaling
promotes medulloblastoma survival via Bc/II. Am J Pathol. 2007;170:
347–355.
32. Berman DM, Karhadkar SS, Maitra A, et al. Widespread requirement
for Hedgehog ligand stimulation in growth of digestive tract tumours.
Nature. 2003;425:846–851.
33. Karhadkar SS, Bova GS, Abdallah N, et al. Hedgehog signalling in
prostate regeneration, neoplasia and metastasis. Nature. 2004;431:
707–712.
34. Fan L, Pepicelli CV, Dibble CC, et al. Hedgehog signaling promotes
prostate xenograft tumor growth. Endocrinology. 2004;145:
3961–3970.
35. Vorechovsky I, Benediktsson KP, Toftgard R. The patched/hedgehog/
smoothened signalling pathway in human breast cancer: no evidence
for H133Y SHH, Ptch and SMO mutations. Eur J Cancer. 1999;35:
711–713.
36. Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA,
Baylin SB. Hedgehog signalling within airway epithelial progenitors
and in small-cell lung cancer. Nature. 2003;422:313–317.
37. Hegde GV, Munger CM, Emanuel K, et al. Targeting of sonic
hedgehog-GLI signaling: a potential strategy to improve therapy for
mantle cell lymphoma. Mol Cancer Ther. 2008;7:1450–1460.
38. Hegde GV, Peterson KJ, Emanuel K, et al. Hedgehog-induced
survival of B-cell chronic lymphocytic leukemia cells in a stromal cell
microenvironment: a potential new therapeutic target. Mol Cancer Res.
2008;6:1928–1936.
39. Dierks C, Grbic J, Zirlik K, et al. Essential role of stromally induced
hedgehog signaling in B-cell malignancies. Nat Med. 2007;13:
944–951.
40. Warzecha J, Bonke L, Koehl U, et al. The hedgehog inhibitor
cyclopamine induces apoptosis in leukemic cells in vitro. Leuk
Lymphoma. 2008;49:2383–2386.
41. Katoh Y, Katoh M. Hedgehog target genes: mechanisms of
carcinogenesis induced by aberrant hedgehog signaling activation. Curr
Mol Med. 2009;9:873–886.
42. Varnat F, Duquet A, Malerba M, et al. Human colon cancer epithelial
cells harbour active HEDGEHOG-GLI signalling that is essential
for tumour growth, recurrence, metastasis and stem cell survival and
expansion. EMBO Mol Med. 2009;1:338–351.
43. Feldmann G, Dhara S, Fendrich V, et al. Blockade of hedgehog signaling
inhibits pancreatic cancer invasion and metastases: a new paradigm for
combination therapy in solid cancers. Cancer Res. 2007;67:2187–2196.
44. Rasheed ZA, Yang J, Wang Q, et al. Prognostic signif icance
of tumorigenic cells with mesenchymal features in pancreatic
adenocarcinoma. J Natl Cancer Inst. 2010;102:340–351.
45. Hui CC, Angers S. Gli proteins in development and disease. Annu Rev
Cell Dev Biol. 2011;27:513–537.
46. Scales SJ, de Sauvage FJ. Mechanisms of Hedgehog pathway activation
in cancer and implications for therapy. Trends Pharmacol Sci.
2009;30:303–312.
47. Sasaki H, Nishizaki Y, Hui C, Nakafuku M, Kondoh H. Regulation
of Gli2 and Gli3 activities by an amino-terminal repression domain:
implication of Gli2 and Gli3 as primary mediators of Shh signaling.
Development. 1999;126:3915–3924.
48. Wicking C, McGlinn E. The role of hedgehog signalling in
tumorigenesis. Cancer Lett. 2001;173:1–7.
49. Ruiz i Altaba A. Therapeutic inhibition of Hedgehog-GLI signaling
in cancer: epithelial, stromal, or stem cell targets? Cancer Cell.
2008;14:281–283.
50. Ruiz i Altaba A, Sanchez P, Dahmane N. Gli and hedgehog in cancer:
tumours, embryos and stem cells. Nat Rev Cancer. 2002;2:361–372.
51. Yauch RL, Gould SE, Scales SJ, et al. A paracrine requirement for
hedgehog signalling in cancer. Nature. 2008;455:406–410.

Cancer Management and Research 2013:5

Dovepress
52. Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched,
a candidate gene for the basal cell nevus syndrome. Science. 1996;272:
1668–1671.
53. Unden AB, Zaphiropoulos PG, Bruce K, Toftqard R, Stahle-Backdahl M.
Human patched (Ptch) mRNA is overexpressed consistently in tumor
cells of both familial and sporadic basal cell carcinoma. Cancer Res.
1997;57:2336–2340.
54. Dahmane N, Lee J, Robins P, Heller P, Ruiz i Altaba A. Activation of
the transcription factor Gli1 and the Sonic hedgehog signalling pathway
in skin tumours. Nature. 1997;389:876–881.
55. Aszterbaum M, Rothman A, Johnson RL, et al. Identification of
mutations in the human PATCHED gene in sporadic basal cell
carcinomas and in patients with the basal cell nevus syndrome. J Invest
Dermatol. 1998;110:885–888.
56. Reifenberger J, Wolter M, Weber RG, et al. Missense mutations in
SMOH in sporadic basal cell carcinomas of the skin and primitive
neuroectodermal tumors of the central nervous system. Cancer Res.
1998;58:1798–1803.
57. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev
Cancer. 2008;8:743–754.
58. Reifenberger J, Wolter M, Knobbe CB, et al. Somatic mutations in the
Ptch, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas.
Br J Dermatol. 2005;152:43–51.
59. Robarge KD, Brunton SA, Castanedo GM, et al. GDC-0449-a potent
inhibitor of the hedgehog pathway. Bioorg Med Chem Lett. 2009;19:
5576–5581.
60. Graham RA, Lum BL, Cheeti S, et al. Pharmacokinetics of hedgehog
pathway inhibitor vismodegib (GDC-0449) in patients with locally
advanced or metastatic solid tumors: the role of alpha-1-acid
glycoprotein binding. Clin Cancer Res. 2011;17:2512–2520.
61. Giannetti AM, Wong H, Dijkgraaf GJ, et al. Identif ication,
characterization, and implications of species-dependent plasma protein
binding for the oral Hedgehog pathway inhibitor vismodegib (GDC0449). J Med Chem. 2011;54:2592–2601.
62. Graham RA, Lum BL, Morrison G, et al. A single dose mass balance
study of the Hedgehog pathway inhibitor vismodegib (GDC-0449)
in humans using accelerator mass spectrometry. Drug Metab Dispos.
2011;39:1460–1467.
63. Wong H, Chen JZ, Chou B, et al. Preclinical assessment of the
absorption, distribution, metabolism and excretion of GDC-0449
(2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)
benzamide), an orally bioavailable systemic Hedgehog signalling
pathway inhibitor. Xenobiotica. 2009;39:850–861.

Vismodegib for treatment of basal cell carcinoma
64. Yue Q, Chen YH, Mulder T, et al. Absorption, distribution, metabolism,
and excretion of [ 14C]GDC-0449 (vismodegib), an orally active
hedgehog pathway inhibitor, in rats and dogs: a unique metabolic
pathway via pyridine ring opening. Drug Metab Dispos. 2011;39:
952–965.
65. LoRusso PM, Jimeno A, Dy G, et al. Pharmacokinetic dose-scheduling
study of hedgehog pathway inhibitor vismodegib (GDC-0449) in
patients with locally advanced or metastatic solid tumors. Clin Cancer
Res. 2011;17:5774–5782.
66. LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog
pathway inhibitor vismodegib (GDC-0449) in patients with refractory,
locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17:
2502–2511.
67. Keating GM. Vismodegib: in locally advanced or metastatic basal cell
carcinoma. Drugs. 2012;72:1535–1541.
68. Aasi S, Silkiss R, Tang JY, et al. New onset of keratoacanthomas after
vismodegib treatment for locally advanced Basal cell carcinomas:
a report of 2 cases. JAMA Dermatol. 2013;149:242–243.
69. Axelson M, Liu K, Jiang X, et al. US Food and drug administration
approval: vismodegib for recurrent, locally advanced, or metastatic
Basal cell carcinoma. Clin Cancer Res. 2013;19:2289–2293.
70. Yauch RL, Dijkgraaf GJ, Alicke B, et al. Smoothened mutation confers
resistance to a Hedgehog pathway inhibitor in medulloblastoma.
Science. 2009;326:572–574.
71. Dijkgraaf GJ, Alicke B, Weinmann L, et al. Small molecule inhibition
of GDC-0449 refractory smoothened mutants and downstream
mechanisms of drug resistance. Cancer Res. 2011;71:435–444.
72. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS,
Rubinstein L et al. New guidelines to evaluate the response to treatment
in solid tumors. European Organization for Research and Treatment of
Cancer, National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.
73. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of
vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366:
2171–2179.
74. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the
hedgehog pathway in patients with the basal-cell nevus syndrome.
N Engl J Med. 2012;366:2180–2188.
75. Chang AL, Oro AE. Initial assessment of tumor regrowth after
vismodegib in advanced Basal cell carcinoma. Arch Dermatol. 2012;148:
1324–1325.

Cancer Management and Research

Dovepress

Publish your work in this journal
Cancer Management and Research is an international, peer-reviewed
open access journal focusing on cancer research and the optimal use of
preventative and integrated treatment interventions to achieve improved
outcomes, enhanced survival and quality of life for the cancer patient.
The journal welcomes original research, clinical & epidemiological

studies, reviews & evaluations, guidelines, expert opinion & commentary, case reports & extended reports. The manuscript management
system is completely online and includes a very quick and fair peerreview system, which is all easy to use. Visit http://www.dovepress.com/
testimonials.php to read real quotes from published authors.

Submit your manuscript here: http://www.dovepress.com/cancer-management-and-research-journal

Cancer Management and Research 2013:5

submit your manuscript | www.dovepress.com

Dovepress

203

